Gymnemagenin

Gymnemagenin
Product Name Gymnemagenin
CAS No.: 22467-07-8
Catalog No.: CFN90961
Molecular Formula: C30H50O6
Molecular Weight: 506.71 g/mol
Purity: >=98%
Type of Compound: Triterpenoids
Physical Desc.: Powder
Targets: Liver X Receptor
Source: The leaves of Gymnema sylvestre.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $268/10mg
Gymnemagenin is a potent and selective antagonist for the β isoform of LXR, it has antihyperglycemic activity, it can be considered further for development into a potent anti-diabetic drug.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Journal of Food Hygiene and Safety2019, 34(5):413-420
  • STAR Protoc.2024, 5(2):102990.
  • Front Immunol.2020, 11:598556.
  • Industrial Crops and Products2018, 353-362
  • University of Stuttgart2021, 11682.
  • Int J Mol Sci.2022, 23(21):13112.
  • Biomed Pharmacother.2022, 156:113929.
  • Molecules.2023, 28(8):3503.
  • Int J Mol Sci.2023, 24(15):12397.
  • Cancers (Basel).2023, 15(1):37.
  • Soyasapogenol D

    Catalog No: CFN91069
    CAS No: 65892-76-4
    Price: $463/5mg
    Melilotigenin C

    Catalog No: CFN99870
    CAS No: 188970-21-0
    Price: Inquiry(manager@chemfaces.com)
    Melilotigenin B

    Catalog No: CFN97479
    CAS No: 91269-84-0
    Price: Inquiry(manager@chemfaces.com)
    alpha-Boswellic acid

    Catalog No: CFN98704
    CAS No: 471-66-9
    Price: $238/20mg
    3-O-Acetyl-alpha-boswellic acid

    Catalog No: CFN90529
    CAS No: 89913-60-0
    Price: $338/10mg
    Beta-Peltoboykinolic acid

    Catalog No: CFN96343
    CAS No: 24778-48-1
    Price: Inquiry(manager@chemfaces.com)
    Erythrodiol 3-palmitate

    Catalog No: CFN98004
    CAS No: 19833-13-7
    Price: Inquiry(manager@chemfaces.com)
    23-Hydroxylongispinogenin

    Catalog No: CFN90948
    CAS No: 42483-24-9
    Price: $268/5mg
    Gymnestrogenin

    Catalog No: CFN90966
    CAS No: 19942-02-0
    Price: $268/5mg
    Gymnemagenin

    Catalog No: CFN90961
    CAS No: 22467-07-8
    Price: $268/10mg
    J Theor Biol. 2016 Feb 21;391:95-101.
    In-silico analysis of gymnemagenin from Gymnema sylvestre (Retz.) R.Br. with targets related to diabetes.[Pubmed: 26711684 ]
    Diabetes is a metabolic disorder characterized by higher than normal glucose in the blood. Most oral hypoglycemic drugs available in market produce adverse side effects which have resulted in continued search for new therapeutic agents with little or no side effects. Herbal drugs are considered relatively safer alternatives and Gymnema sylvestre is one of the most well established natural remedy for diabetes and is traded worldwide under several brands.
    METHODS AND RESULTS:
    In the present study an attempt has been made to use in silico techniques to understand and predict the drug likeliness of Gymnemagenin, one of the key constituents of G. sylvestre against 15 proteins having key role in carbohydrate metabolism. Gymnemagenin was found to dock well with crystallographic structures of 7 of the 15 selected targets and was found even better than the two known clinically used antidiabetic compounds, repaglinide and sitagliptin taken in the study for comparison.
    CONCLUSIONS:
    Gymnemagenin therefore can be considered further for development into a potent anti-diabetic drug.
    J Agric Food Chem. 2012 Mar 14;60(10):2517-24.
    Hypoglycemic activity of Gymnema sylvestre extracts on oxidative stress and antioxidant status in diabetic rats.[Pubmed: 22360666 ]
    Diabetes mellitus, which is associated with oxidative damage, has a significant impact on health, quality of life, and life expectancy. An ethanol extract of Gymnema sylvestre leaf was examined in vitro and in vivo to investigate the role of antioxidants in diabetic rats.
    METHODS AND RESULTS:
    The extract exhibited strong antioxidant activity in the assays, including TBA (56%), SOD-like (92%), and ABTS (54%). Blood glucose levels in the diabetic rats fed G. sylvestre extract decreased to normal levels. The presence of the antihyperglycemic compounds Gymnemagenin and gymnemic acids in G. sylvestre extract was detected by LC/MS analysis. Lipid peroxidation levels were decreased by 31.7% in serum, 9.9% in liver, and 9.1% in kidney in the diabetic rats fed the extract. Feeding G. sylvestre extract to the diabetic rats decreased the activity of glutathione peroxidase in cytosolic liver and glutamate pyruvate transaminase in serum to normal levels.
    Steroids. 2015 Apr;96:121-31.
    Molecular decodification of gymnemic acids from Gymnema sylvestre. Discovery of a new class of liver X receptor antagonists.[Pubmed: 25668616]
    The individual chemical components of commercial extract of Gymnema sylvestre, a medicinal plant used in the traditional systems of the Indian medicine for its antidiabetic and hypolipidemic properties, were isolated and evaluated for their capability to act as modulators of nuclear and membrane receptors involved in glucose and lipid homeostasis.
    METHODS AND RESULTS:
    The study disclosed for the first time that individual gymnemic acids are potent and selective antagonists for the β isoform of LXR. Indeed the above activity was shared by the most abundant aglycone Gymnemagenin (10) whereas gymnestrogenin (11) was endowed with a dual LXRα/β antagonistic profile. Deep pharmacological investigation demonstrated that gymnestrogenin, reducing the expression of SREBP1c and ABCA1 in vitro, is able to decrease lipid accumulation in HepG2 cells.
    CONCLUSIONS:
    The results of this study substantiate the use of G. sylvestre extract in LXR mediated dislypidemic diseases.
    Lucidumol A

    Catalog No: CFN95059
    CAS No: 217476-73-8
    Price: $318/5mg
    1-Phenyl-2-propanol

    Catalog No: CFN95129
    CAS No: 14898-87-4
    Price: $30/20mg
    Cassiaglycoside II

    Catalog No: CFN95130
    CAS No: 2241081-56-9
    Price: $368/5mg
    Citrusin B

    Catalog No: CFN95178
    CAS No: 105279-10-5
    Price: $388/5mg
    Neoarctin B

    Catalog No: CFN95243
    CAS No: 155969-67-8
    Price: $318/10mg
    Vicinin 2

    Catalog No: CFN95249
    CAS No: 90456-53-4
    Price: $368/5mg
    Nortrachelogenin-5'-C-beta-glucoside

    Catalog No: CFN95251
    CAS No: 858127-39-6
    Price: $318/10mg
    Cannabisin A

    Catalog No: CFN95287
    CAS No: 130508-46-2
    Price: $318/5mg
    Beta-Dimorphecolic acid (9(S)-HODE)

    Catalog No: CFN95313
    CAS No: 18104-44-4
    Price: $318/5mg
    Ganolucidic acid D

    Catalog No: CFN95472
    CAS No: 102607-22-7
    Price: $413/5mg